miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma
<i>Background:</i> MYC is a master regulator of multiple myeloma (MM) by orchestrating several pro-tumoral pathways, including reprograming of the miRNA transcriptome. MYC is also involved in the acquirement of resistance to anti-MM drugs, including immunomodulatory imide drugs (IMiDs)....
Main Authors: | Daniele Caracciolo, Caterina Riillo, Giada Juli, Francesca Scionti, Katia Todoerti, Nicoletta Polerà, Katia Grillone, Lucia Fiorillo, Mariamena Arbitrio, Maria Teresa Di Martino, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/17/4365 |
Similar Items
-
miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy
by: Maria Teresa Di Martino, et al.
Published: (2021-03-01) -
Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome
by: Benjamin Chu, et al.
Published: (2014-10-01) -
Database study of lenalidomide (Revlimid) in Germany: monitoring off-label use [Monitoring des Off-Label-Use von Lenalidomid (Revlimid) in Deutschland]
by: Dörks, Michael, et al.
Published: (2013-07-01) -
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2014-08-01) -
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
by: Maria Teresa Di Martino, et al.
Published: (2020-06-01)